Literature DB >> 23031358

Expression of androgen receptors in triple negative breast carcinomas.

Ivana Mrklić1, Zenon Pogorelić, Vesna Capkun, Snježana Tomić.   

Abstract

Triple negative breast cancer (TNBC) consists of a group of tumors with poor prognosis, owing to aggressive tumor biology and lack of targeted therapy. The aim of this study was to assess the immunostaining for androgen receptors (ARs) in the group of TNBC, in addition to basal-like (BL) immunophenotype, BL morphology and conventional clinicopathological factors and to demonstrate its prognostic relevance in this group of tumors. The study included 83 patients. Slides were stained immunohistochemically for estrogen and progesterone receptors, HER2, CK5/6, CK14, EGFR, Ki-67 and AR. Of the 83 TNBC samples, 32.5% showed positive immunostaining for AR, 66.3% had BL immunophenotype, and 48.2% had BL morphology. Positive AR immunostaining was inversely correlated with higher clinical stage, higher mitotic score, higher histological grade and higher proliferation index measured by Ki-67. Significantly more AR negative tumors were observed among the tumors with BL immunophenotype and BL morphology. There was no significant association between positive AR immunostaining and disease free survival or overall survival. More than one third of TNBC were AR-positive, and this represents a potential opportunity for novel targeted treatment in the group of breast tumors for which therapeutic options are currently limited.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23031358     DOI: 10.1016/j.acthis.2012.09.006

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  40 in total

Review 1.  Role of the androgen receptor in triple-negative breast cancer.

Authors:  Murtuza Rampurwala; Kari B Wisinski; Ruth O'Regan
Journal:  Clin Adv Hematol Oncol       Date:  2016-03

2.  Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.

Authors:  Tetsuyo Maeda; Yoko Nakanishi; Yukari Hirotani; Fumi Fuchinoue; Katsuhisa Enomoto; Kenichi Sakurai; Sadao Amano; Norimichi Nemoto
Journal:  Med Mol Morphol       Date:  2015-05-26       Impact factor: 2.309

3.  Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study.

Authors:  Ya-Xuan Liu; Ke-Jing Zhang; Li-Li Tang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

4.  Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.

Authors:  J Feng; L Li; N Zhang; J Liu; L Zhang; H Gao; G Wang; Y Li; Y Zhang; X Li; D Liu; J Lu; B Huang
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

Review 5.  Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.

Authors:  Guilhem Roubaud; Bobby C Liaw; William K Oh; David J Mulholland
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

6.  Androgen Receptor Expression in Breast Carcinoma of Egyptian Patients.

Authors:  Rehab Monir Samaka; Sheren Fouad Younes
Journal:  J Clin Diagn Res       Date:  2016-11-01

7.  Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.

Authors:  Valerie N Barton; Nicholas C D'Amato; Michael A Gordon; Hanne T Lind; Nicole S Spoelstra; Beatrice L Babbs; Richard E Heinz; Anthony Elias; Paul Jedlicka; Britta M Jacobsen; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2015-02-23       Impact factor: 6.261

8.  Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.

Authors:  Valerie N Barton; Jessica L Christenson; Michael A Gordon; Lisa I Greene; Thomas J Rogers; Kiel Butterfield; Beatrice Babbs; Nicole S Spoelstra; Nicholas C D'Amato; Anthony Elias; Jennifer K Richer
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

9.  Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Authors:  Damoun Safarpour; Shabnam Pakneshan; Fattaneh A Tavassoli
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

10.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Authors:  Gilda Schmidt; Christoph Gerlinger; Ingolf Juhasz-Böss; Elmar Stickeler; Achim Rody; Cornelia Liedtke; Pauline Wimberger; Theresa Link; Eberhard Müller; Tanja Fehm; Manuela Abel; Stefan Stein; Rainer Bohle; Jan Endrikat; Erich-Franz Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-23       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.